Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

Movement Disorders

Volumn 22, Issue 2, 2007, Pages 179-186

  Goetz, Christopher G ^a   Damier, Philippe ^b   Hicking, Christine ^c   Laska, Eugene ^d,e   Müller, Thomas ^f   Olanow, C Warren ^g   Rascol, Olivier ^h   Russ, Hermann ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b CHU de Nantes   (France)

^c MERCK KGAA   (Germany)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Dyskinesias; Parkinson's disease; Randomized clinical trials; Sarizotan

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SARIZOTAN; TOLCAPONE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO;

ADULT; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; PARKINSON DISEASE; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 33847757879     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21226     Document Type: Article

References (15)

1. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20(Suppl. 11):S11-S16.
2. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
3. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
4. 1A agonist improves motor complications in rodent and primate Parkinsonian models. Neurology 2001;57:1829-1834.
5. Langston JW, Quik M, Petzinger G, Jakowec M, DiMonte DA. Investigating levodopa-induced dyskinesias in the Parkinsonian primate. Ann Neurol 2000;47(Suppl. 1):S79-S89.
6. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label trial of sarizotan in Parkinson's disease patients with levodopa-induced dyskinesias (SPLENDID study). Clin Neuropharmacol 2004;27:58-62.
7. Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
8. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
9. Guy W. Abnormal Involuntary Movement Scale. ECDEU assessment manual for psychopharmacology. Washington, DC: Government Printing Office; 1976. p 534-537.
10. Fahn S, Elton EL and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information Publications; 1987. p 153-163.
11. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710-714.
12. Goetz CG, Leurgans S, Raman R, Parkinson Study Group. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002;17:283-288.
13. Stone AA, Shiffman S, Schwartz JE, et al. Patient compliance with paper and electronic diaries. Control Clin Trials 2003;24:182-189.
14. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the UPDRS. Mov Disord 2006;21:1200-1207.
15. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposal. Arch Gen Psychiatry 2006;63:484-489.